Supplemental exogenous agmatine could ameliorate the lipopolysaccharide-induced systemic inflammatory responses and multiple organ injuries through the 2 receptor”>imidazoline I2 receptor-ribosomal S6 kinase 2-nuclear factor-κB pathway.

Agmatine could be used as both a clinical biomarker and a promising pharmaconutrient in patients with severe sepsis.

Serum agmatine levels were significantly decreased in patients with sepsis and lipopolysaccharide-induced mice, and correlated with Acute Physiology and Chronic Health Evaluation II score, procalcitonin, tumor necrosis factor-α, and interleukin-6 levels.

In a therapeutic experiment, exogenous agmatine attenuated the cytokine production of peripheral blood mononuclear cells from patients with sepsis and healthy controls.

Read More